Brief Communication
College in collaboration with Suraksha Clinics (Departments of Dermatology and Obstetrics and Gynaecology, J.N. Medical College, Malkhan Singh Male and Female District Hospital, Aligarh) and Anti-Retroviral Centre, J.N. Medical College, Aligarh. Patients who had already received the treatment for STI were excluded from this study. The study group comprised individuals presenting with one or more of the complaints as enunciated by the WHO in its syndromic approach for the diagnosis of STI. [4] Relevant clinical signs and symptoms were as follows: (i) urethral, cervical and vaginal discharge (whitish, yellowish or greenish, frothy or foul smelling); (ii) genital ulcer, treponemal and herpetic ulcer; (iii) burning micturition, lower abdominal pain, itching, etc. STIs provisionally diagnosed by clinical features were confirmed by the standard laboratory techniques, using appropriately collected specimens. [1] Techniques for antimicrobial susceptibility testing of
Neisseria gonorrhoeae
The disc diffusion technique was employed as the initial susceptibility test. Antimicrobial agents tested were penicillin (0.5 IU), ciprofloxacin (1 ug), nalidixic acid (30 ug), ceftriaxone (0.5 ug), cefpodoxime (10 ug), spectinomycin (100 ug), tetracycline (10 ug), azithromycin (15 ug) and cefixime (10 µg). All the isolates were sent to Apex Regional STD Teaching, Training and Research Centre (WHO GASP SEAR Regional Reference Laboratory), Safdarjung Hospital, New Delhi, for confirmation of disc diffusion results and interpretation was done according to Bala et al., 2015 . [5] Genotypic detection of gyrA, parC and blaTEM Detection of gyrA and parC genes is considered as the reference method for determining resistance to fluoroquinolones, while blaTEM detects resistance to penicillin. Polymerase chain reaction amplification was carried with primers targeting gyrA, parC and blaTEM genes as given below [ Table 1 ]. [6] Sequencing DNA sequencing was performed at Triyat Scientific CO. (Nagpur, India) using the ABI Prism® BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, USA), with forward and reverse primers of gyrA gene on 3730xl Genetic Analyzer (Applied Biosystems, USA), separately. Phylogenetic analysis was performed using the software MEGA, version 4, after multiple alignments of data using CLUSTAL X. rEsults N. gonorrhoea was identified in 10 male patients. Table 2 furnishes the information on all the STIs identified in this study. All the N. gonorrhoea isolates were sensitive to azithromycin, spectinomycin and cefixime, while one isolate was resistant to ceftriaxone and cefpodoxime, as seen in Figure 1 .
Minimal inhibitory concentration (MIC) 90 for ciprofloxacin was ≥4 µg/ml, for penicillin was ≥6 µg/ml and for tetracycline was 12 µg/ml, which clearly brackets them as resistant isolates [ Table 3 ]. In this study, all isolates were quinolone-resistant N. gonorrhoeae (QRNG), 5/7 were penicillinase-producing N. gonorrhoeae (PPNG), 1/7 was chromosomally mediated penicillin-resistant N. gonorrhoeae (CMPRNG) and 3/7 were tetracycline-resistant N. gonorrhoeae (TRNG).
TEM was detected in six out of seven cases. As expected, the one sensitive penicillin strain did not possess TEM gene. In all cases, gyrA and parC (resistance genes against quinolones) were observed. DNA sequencing of gyr A for all the seven representative strains is shown in Figure 2 .
DiscussiOn
Patients with urethritis mainly comprised male patients, with complaints of painful urethral discharge and burning [7] Antibiotic resistance poses an important obstacle in the prevention and control of N. gonorrhoea. [8] In our study, resistance was observed against ceftriaxone and cefpodoxime in 14.2% of cases. Four patients were sensitive and three patients were resistant to tetracycline. A large number (85.8%) of cases were resistant to penicillin. Alarmingly, 100% resistance was observed against nalidixic acid and ciprofloxacin. Other Indian studies have also reported increase in the spectrum and level of antibiotic resistance of N. gonorrhoeae isolates in recent years as compared to that seen previously. [5, 9] In our study, penicillin resistance escalated to 85.8%, compared to 33% in 2002. [10] Ciprofloxacin-resistant isolates increased from 74% to 100%, which mirrors our resistance profile against fluoroquinolones. [11] In our study, one case exhibited resistance to ceftriaxone and cefpodoxime. Isolates showing lower susceptibility to ceftriaxone appeared from 1999 onwards with one in 1999 and two each in 2000, 2001 and 2002, respectively. [11] Cefixime with azithromycin is the first-line treatment recommended under syndromic management of STIs according to the recent NACO guidelines for treatment of gonorrhoea. In our study, all the strains tested were sensitive to azithromycin and cefixime, indicating that kit 1 (comprising azithromycin and cefixime) as approved by NACO for syndromic management of discharge patients was appropriate. However, all the patients tested were QRNG, 5/7 were PPNG, 1/7 was CMPRNG and 4/7 were TRNG.
MIC90 was high for ciprofloxacin (≥4 µ g/ml), penicillin (≥6 µg/ml) and tetracycline (12 µg/ml). MIC90 of ceftriaxone, spectinomycin, azithromycin and cefpodoxime was ≤0.03 µg/ml, ≤16 µg/ml, ≤0.5 µg/ml and ≤0.023 µg/ml, respectively. In a study by Kulkarni et al., minimum inhibitory concentration (90%) for ciprofloxacin, tetracycline, penicillin, ceftriaxone and spectinomycin was 32, 4, 12, 0.008 and 8 µg/ml, respectively. [11] The presence of TEM (resistance gene against penicillin) was confirmed genotypically. In all seven cases, gyrA and parC (resistance genes against quinolones) were observed, thus confirming their QRNG status. Apart from reference centres (PGI Chandigarh and WHO GASP SEAR Regional Reference Laboratory, Safdarjung Hospital, New Delhi), we are the sole centre from North India who have confirmed the resistance genotypically. Sequencing was performed to confirm the genotypic results. Relatedness was observed in all three sequences (TEM, gyrA and parC) in comparison to sequences obtained from NCBI database.
cOnclusiOn
The alarming increase in the resistance to commonly used antimicrobials for gonorrhoea indicates the need for prudence in their use by the STI treatment providers and highlights the importance of laboratory-based surveillance, for guidance in appropriate management guidelines of gonococcal urethritis.
